Navigation Links
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Date:11/21/2007

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 19th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2007, at 9:00 a.m. EST (6:00 a.m. PST). The conference is being held at the Pierre Hotel in New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through December 11, 2007.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C virus (HCV) infection and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel small molecule medic
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... The congress of the ERA-EDTA (European Renal Association ... congress in Europe on nephrology ... Istanbul to share their knowledge ... have been presented: / (1) Gupta, A ... REDUCES ESA USE" By SFP-iron administration, the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 ... services company for clinical trials, announced today it ... Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce ... payment process. SpendMD ™, Aggregate Spend ... solution for tracking and reporting transfer of value ...
(Date:5/21/2013)... New York , May 21, 2013 ... by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products ... Research, IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, ... 2.4 billion in 2011 and is expected to grow ... to reach an estimated value of USD 4.7 billion ...
(Date:5/21/2013)... 2013 Many have long discussed the ... acne. Recently physicians from Clinical Psychiatry.com readdressed ... the skin, and suggested using hypnotherapy and ... produced from stress that cause acne. , Doctors in ... acne brings about, stress causes changes in the skin ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2
... Better Understanding ... 15 Results from the Global Longitudinal,study of Osteoporosis in ... do not believe they are at a higher risk of,fractures ... than,60,000 women over age 55 and was presented today at ...
... September 15 , - Oncentra(R) RT Viewer* ... September 14-18 and ASTRO 2008, Boston, USA, September,21-24, ... today,announced the market release of Oncentra RT Viewer. ... allows clinicians to review,radiotherapy plans that are generated ...
... 12 Fougera, a division of Nycomed,US Inc., ... Cream USP,1%. The generic formulation compares to Taro,s ... sizes: 15g tubes (NDC # 0168-0133-15), 30g tubes,(NDC ... "The approval of Clotrimazole Cream is another ...
Cached Biology Technology:Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures 2Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures 3Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy 2
(Date:5/21/2013)... Chicago College of Medicine will study gender differences in how ... source -- and how changes in fat metabolism play a ... grant from the National Heart, Lung and Blood Institute. , ... energy. These changes may play a major role in the ... women, says E. Douglas Lewandowski, director of the UIC Center ...
(Date:5/21/2013)... of insulin action in cells in precise detail like ... what goes wrong in diabetes. , The breakthrough ... from Sydney,s Garvan Institute of Medical Research, is now ... journal Cell Metabolism . , First discovered in ... in the body because it helps us lower blood ...
(Date:5/20/2013)... about the effect of physical education (PE) on child ... that increasing the amount of time that elementary schoolchildren ... , The study represents some of the first evidence ... and is forthcoming in the Journal of Health ... study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Gym class reduces probability of obesity, study finds for first time 2
... time impact the delivery of drugs and explain a ... nanoparticles that can penetrate a cell without poking a ... The key to their approach? Stripes. The team ... two different kinds of molecules can quickly pass into ...
... Spanish . Networks for radiological monitoring ... environment and detect possible incidents. The PhD thesis ... the University of the Basque Country provides a ... radiological incidents caused externally. Most countries ...
... independent review of social and ethical challenges associated with ... published today (9 June). The report, commissioned by the ... Society Strategy Panel, is part of its programme to ... rapidly emerging area of science and technology. Embargoed copies ...
Cached Biology News:MIT: Stripes key to nanoparticle drug delivery 2More sensitive radiology monitoring in the Basque Country 2More sensitive radiology monitoring in the Basque Country 3Synthetic Biology: funders move to address social and ethical challenges 2
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Control primers and template for 5kb and 15 kb products....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
... Klein Taq is a derivative of Taq ... truncated Thermus aquaticus DNA polymerase. Expressed from ... initiates at Met236, bypassing the 5'-3' exonuclease ... enzyme reveals a highly active and even ...
Biology Products: